US seeking more transparency from pharma.

The article reports on the call of the U.S. government for a greater transparency from pharmaceutical companies over concerns of rising drug costs, as outlined in the budget for 2017 fiscal year released on February 9, 2016. It notes that the budget proposes granting the Health and Human Services Department the authority to require drug manufacturers to publicly disclose information, including research and development costs, discounts, and other data.